<DOC>
	<DOCNO>NCT02676323</DOCNO>
	<brief_summary>Cancer uncontrolled growth human cell . The growth normal human cell control multiple mechanism . Panobinostat belong class chemotherapy drug call `` histone deacetylase ( HDAC ) inhibitor . '' HDAC inhibitor like panobinostat block enzyme know histone deacetylases , stop cancer cell divide cause die . Fludarabine cytarabine chemotherapy drug commonly use treat pediatric patient refractory relapse acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) . The purpose study test safety panobinostat find high dose panobinostat give safely combined fludarabine cytarabine . This pilot study do two part : The goal Part 1 study find high tolerable dose panobinostat give patient AML MDS , combine fludarabine cytarabine . Once dose determine , participant enrol Part 2 : Dose Expansion , look effect panobinostat/fludarabine/cytarabine combination patient leukemia/MDS . PRIMARY OBJECTIVE : - Determine tolerable dose panobinostat give combination fludarabine cytarabine pediatric patient relapse refractory AML MDS . SECONDARY OBJECTIVES : - Characterize pharmacokinetics panobinostat first dose steady-state . - Estimate overall response rate combination panobinostat , fludarabine , cytarabine .</brief_summary>
	<brief_title>Panobinostat With Fludarabine Cytarabine Treatment Children With Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>STUDY PART 1 : Dose Escalation Cohort During dose escalation phase ( Part 1 ) , participant receive one course panobinostat plus fludarabine cytarabine . The start dose panobinostat 10 mg/m^2/dose , 2 additional dose level 15 20 , depend tolerability . Each course 12 day STUDY PART 2 : Dose Expansion Cohort The recommended phase 2 dose ( RP2D ) choose base maximum tolerate dose ( MTD ) totality data obtain study Part 1 . Additional patient enrol , need , least 6 patient treat recommended RP2D confirm MTD panobinostat give study Part 2 . After final MTD determination , 12 additional participant treat dose level evaluation tolerability response , include complete toxicity data estimation response rate combination panobinostat , fludarabine , cytarabine .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Participants must diagnosis AML MDS must disease relapsed refractory chemotherapy , relapse hematopoietic stem cell transplantation ( HSCT ) . Refractory disease define persistent disease least two course induction chemotherapy . Patients AML must ≥ 5 % leukemic blast bone marrow increase level minimal residual disease ( MRD ) bone marrow assess flow cytometry . If adequate bone marrow sample obtain , patient may enrol unequivocal evidence leukemia peripheral blood . Adequate organ function define follow : Direct bilirubin ≤ 1.5 x institutional upper limit normal ( IULN ) AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 x ULN Creatinine ≤ 1.5 x ULN age Serum albumin &gt; 3.0 g/dl Left ventricular ejection fraction ≥ 40 % shorten fraction ≥ 25 % . Age ≤ 24 year Patients must able swallow capsule Performance status : Lansky ≥ 50 patient ≤ 16 year old Karnofsky ≥ 50 % patient &gt; 16 year old . Patients must fully recover acute effect prior therapy must meet following criterion : At least 14 day must elapse since completion myelosuppressive therapy At least 24 hour must elapse since completion lowdose chemotherapy , hydroxyurea lowdose cytarabine ( 200 mg/m^2/day ) . For patient receive prior HSCT , evidence GVHD great 60 day must elapse since HSCT . Patients receive therapy , include steroid , treatment prevention GVHD . All medication must discontinue least 24 hour prior enrollment . Body Surface Area : Because small capsule size available panobinostat 10 mg , minimum BSA allow enrollment Dose Level 1 0.85 m^2 . The minimum Dose Level 2 BSA=0.6 m^2 minimum Dose Level 3 BSA=0.42 m^2 . Must pregnant breastfeeding . Female patient sexually active childbearing potential must agree use dual method contraception negative serum pregnancy test screening , male patient sexually active must use effective barrier method contraception sexually active female childbearing potential . For male female patient sexually active , effective method contraception must use throughout study three month follow last dose . Abstinence acceptable form contraception . Patients Down syndrome , acute promyelocytic leukemia , juvenile myelomonocytic leukemia , Fanconi anemia , Kostmann syndrome , Shwachman syndrome , bone marrow failure syndromes eligible . Use investigational agent within 30 day . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , study participation , follow , interpretation study research . Uncontrolled infection within one week first dose . Infections control concurrent antimicrobial agent acceptable , antimicrobial prophylaxis per institutional guideline acceptable . Known human immunodeficiency virus infection ( prestudy testing require ) . Patient diarrhea &gt; CTCAE grade 2 . ( CTCAE version 4.0 ) Impaired cardiac function clinically significant cardiac disease , history arrhythmia ( include ventricular fibrillation torsade de pointes ) , bradycardia &lt; 50 bpm , screen ECG prolong QTc ( &gt; 450 msec ) , uncontrolled hypertension history presence sustain ventricular tachyarrhythmia . Impairment GI function GI disease may significantly alter absorption panobinostat . Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start treatment . Granisetron may administer , antiemetic associate QT prolongation ( e.g. , ondansetron ) allow .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>Childhood leukemia</keyword>
	<keyword>Hematological malignancy</keyword>
</DOC>